Psilocybin fungi, also more informally known as psychedelic mushrooms, have a rich, cultural history and were criminalized in the 1970s. However, recent developments, including Food and Drug Administration breakthrough status and state-level legalization, revive interest in these substances. They may be able to treat many disorders without the addictiveness or risk of overdose of cocaine, heroin, methamphetamine, and other psychoactive chemicals. This article analyzes the therapeutic potential and economic impact of psilocybin amid its nationwide decriminalization. Oregon and Colorado are at the forefront, anticipating changes in legislation, while approximately 25 states are contemplating measures. The cost-effectiveness of psilocybin in the treatment of mental health disorders, addiction, and positive legal indications highlights its appeal. Yet, ethical considerations, careful prescription methods, and strategic legalization are highlighted. This article calls for continuous research, adherence and understanding of ethical standards, and a holistic approach to psilocybin’s accessibility for potential therapeutic advantages.
Get full access to this article
View all access options for this article.
References
1.
Carod-ArtalFJ. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia, 2015; 30(1):42–49.
CoppolaM, BevioneF, MondolaR. Psilocybin for treating psychiatric disorders: A psychonaut legend or a promising therapeutic perspective? J Xenobiot, 2022; 12(1):41–52.
7.
KargboRB. Psilocybin therapeutic research: The present and future paradigm. ACS Med Chem Lett, 2020; 11(4):399–402.
8.
DanielD. “It kind of polishes all your flaws away”: Long-term experiences with psilocybin mushrooms and the influence of set and setting. Cal Poly Humboldt Theses and Projects, 2021; 492. Available from: https://digitalcommons.humboldt.edu/etd/492
9.
MacCallumCA, LoLA, PistawkaCA, DeolJK. Therapeutic use of psilocybin: Practical considerations for dosing and administration. Front Psychiatry, 2022; 13:1040217.
10.
SmithWR, SistiD. Ethics and ego dissolution: The case of psilocybin. J Med Ethics, 2020; 47
11.
HobbsC. The health and clinical benefits of medicinal fungi. Adv Biochem Eng Biotechnol, 2023; 184:285–356.
12.
LingS, CebanF, LuiLMW, et al.Molecular mechanisms of psilocybin and implications for the treatment of depression. CNS Drugs, 2022; 36(1):17–30.
13.
DossMK, PovažanM, RosenbergMD, et al.Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry, 2021; 11(1):574.
14.
MaiaJM, de OliveiraBSA, BrancoLGS, SorianoRN. Therapeutic potential of psychedelics: History, advancements, and unexplored frontiers. Prog Neuropsychopharmacol Biol Psychiatry, 2024; 131:110951.
15.
CurtisR, RobertsLC, GravesEG, et al.The role of psychedelics and counseling in mental health treatment. J Mental Health Counseling, 2020; 42(4):323–338.
16.
MitchellJM, Ot’aloraGM, van der KolkB, et al.MAPP2 Study Collaborator Group. MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nat Med, 2023; 29(10):2473–2480.
MarseilleE, BertozziS, KahnJG. The economics of psychedelic-assisted therapies: A research agenda. Front Psychiatry, 2022; 13:1025726.
19.
GrobCS, DanforthAL, ChopraGS, et al.Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry, 2011; 68(1):71–78.
20.
Garcia-RomeuA, RichardsWA. Current perspectives on psychedelic therapy: Use of serotonergic hallucinogens in clinical interventions. Int Rev Psychiatry, 2018; 30(4):291–316.
21.
MarksM, CohenIG. Psychedelic therapy: A roadmap for wider acceptance and utilization. Nat Med, 2021; 27(10):1669–1671.
HearnBG, BrubakerMD, RichardsonG. Counselors’ attitudes toward psychedelics and their use in therapy. J Counseling Develop, 2022; 100(4):364–373.
24.
SpringerPR, HarrisSM. Attitudes and beliefs of marriage and family therapists regarding psychotropic drugs and therapy. J Marital Fam Ther, 2010; 36(3):361–375.
25.
HaleyJ. The effect of long-term outcome studies on the therapy of schizophrenia. J Marital Fam Ther, 1989; 15(2):127–132.
26.
Agin-LiebesG, DavisAK. Psilocybin for the treatment of depression: A promising new pharmacotherapy approach. Curr Top Behav Neurosci, 2022; 56:125–140.
27.
YadenDB, EarpD, GraziosiM, et al.Psychedelics and psychotherapy: Cognitive-behavioral approaches as default. Front Psychol, 2022; 13:873279.
28.
JonesGM, NockMK. Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension. J Psychopharmacol, 2022; 36(1):66–73.
29.
HendricksPS, CrawfordMS, CropseyKL, et al.The relationships of classic psychedelic use with criminal behavior in the United States adult population. J Psychopharmacol, 2018; 32(1):37–48.
LoweH, ToyangN, SteeleB, et al.The therapeutic potential of psilocybin. Molecules, 2021; 26(10):2948.
32.
CarbonaroTM, BradstreetMP, BarrettFS, et al.Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol, 2016; 30(12):1268–1278.
33.
GoelDB, ZilateS. Potential therapeutic effects of psilocybin: A systematic review. Cureus, 2022; 14(10):e30214.
PrueittWL, SloshowerJ. Psychedelic medicine: Creating an introductory course for mental health professionals and trainees. Acad Psychiatry, 2023; 47(1):74–77.
SiegelJS, DailyJE, PerryDA, NicolGE. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry, 2023; 80(1):77–83.
39.
JohnsonMW, Garcia-RomeuA, GriffithsRR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse, 2017; 43(1):55–60.
40.
JohnsonMW, Garcia-RomeuA, CosimanoMP, GriffithsRR. Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction. J Psychopharmacol, 2014; 28(11):983–992.
41.
BogenschutzMP, RossS, BhattS, et al.Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial [published correction appears in JAMA psychiatry 2022 Sep 14]. JAMA Psychiatry, 2022; 79(10):953–962.
42.
McPheetersM, O’ConnorEA, RileyS, et al.Pharmacotherapy for alcohol ue disorder: A systematic review and meta-analysis. Jama, 2023; 330(17):1653–1665.
43.
BossisA. Psilocybin, spirituality, and palliative care: Research and implications. Altern Complement Therap, 2021; 27(1):14–17.
44.
McCroneP, FisherH, KnightC, et al.Cost-effectiveness of psilocybin-assisted therapy for severe depression: Exploratory findings from a decision analytic model. Psychol Med, 2023; 53:7619–7626.
